43 results about "Diazoxide" patented technology

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

The present invention relates to the use of an effective amount of at least one potassium KvI.3 channel inhibitor or of an effective amount of at least one compound having in addition to its potassium KvI.3 channel inhibiting properties also CBx modulating properties and / or potassium K(atp) channel opening properties for the manufacture of a medicament for the prophylaxis, treatment, delayed progression, delayed onset and / or inhibition of various medical conditions in subjects in need thereof . The diseases are obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity , asthma, glucose metabolism - in particular, insulin resistance, hyperglycaem ea and / or glucose intolerance - neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripher al vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration , pain - including neuropathic pain and chronic pain - and impotence. The compounds are a.o. 4, 5-dihydropyrazole derivatives, imidazole derivatives, diazoxide, NN414, R(+) -WIN55212-2, HU-308, Rimonaband, SR-147778.

The present invention provides benzothiadiazine and chroman derivatives and particularly diazoxide and cromakalim derivatives for use in treating glaucoma, retinopathy, treating age related macular degeneration, treating, stabilizing and / or inhibiting blood and lymph vascularization, and reducing intraocular pressure by administering a pharmaceutically effective amount of a prodrug disposed in an ophthalmically acceptable carrier to the eye, wherein the prodrug specifically modulates a KATP channel to reduce an intraocular pressure.

The invention discloses a method for preparing diazoxide, which comprises anthranilamide and N ‑chlorosuccinimide is reacted in a chlorine solvent to obtain 2‑amino‑5‑chlorobenzenesulfonamide, and 2‑amino‑5‑chlorobenzenesulfonamide, imidazolium salt and amide solvent are mixed and reacted by heating to obtain di Azrazine; or anthranilamide, imidazolium salt and amide solvent are mixed and reacted by heating to obtain compound IV; then compound IV and N - Chloro-succinimide is reacted in a chlorine solvent to obtain diazoxide; the invention also discloses the application of imidazole hydrochloride as a catalyst in the preparation of diazoxide. The invention avoids the problems of using highly corrosive and highly toxic chlorosulfonyl isocyanate, strong acid (sulfuric acid) and high reaction temperature (240-250°C) in the reaction process, and the reaction steps are short; the total yield of the two steps can be It reaches more than 90%, and compared with the preparation method of diazoxide that has been publicly reported, the synthetic route provided by the present invention overcomes many shortcomings, so it is more suitable for industrial production.